...
首页> 外文期刊>The annals of pharmacotherapy >Management of anthracycline extravasation injuries.
【24h】

Management of anthracycline extravasation injuries.

机译:蒽环类药物外渗损伤的处理。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To review the evidence for the management of anthracycline extravasation and determine the optimal treatment of such injuries. DATA SOURCES: A search of MEDLINE (1966-February 2007) and International Pharmaceutical Abstracts (1970-February 2007) was performed using the search terms anthracyclines and extravasation. DATA SYNTHESIS: Extravasation of anthracyclines can have devastating effects. After infiltration of these drugs into the interstitial tissue, damage may range from mild erythema and pain to severe tissue necrosis. Many agents have been studied in the management of these injuries; however, few have demonstrated efficacy and treatment remains controversial. Nonpharmacologic modalities shown to limit extravasation injuries include local tissue cooling and elevation of the affected area. Corticosteroids, sodium bicarbonate, hyaluronidase, hyperbaric oxygen, heparin fractions, alpha-tocopherol, N-acetylcysteine, and granulocyte macrophage-colony stimulating factor have all either been shown to be ineffective or have limited data supporting their use. Topical dimethyl sulfoxide (DMSO) has been shown in prospective studies to limit the course of extravasation injuries. Dexrazoxane has been shown in animal models and case reports to be useful in the management of anthracycline extravasation. Two recent prospective clinical trials examining intravenous dexrazoxane 1000 mg/m2 within 6 hours of extravasation, 1000 mg/m2 24 hours after extravasation, and 500 mg/m2 48 hours after extravasation injuries add to the data supporting the use of this agent in such injuries. Of the 54 patients enrolled, surgery-requiring necrosis was avoided in 98.2%. CONCLUSIONS: The optimal treatment of anthracycline extravasation includes local tissue cooling, elevation of the afflicted extremity, dexrazoxane administration, and possibly topical DMSO. Many other drugs have been investigated; however, due to a lack of data, they cannot be recommended for the management of anthracycline extravasation.
机译:目的:回顾治疗蒽环类药物外渗的证据,并确定此类损伤的最佳治疗方法。数据来源:使用蒽环类药物和外用药的搜索词对MEDLINE(1966年-2007年2月)和International Pharmaceutical Abstracts(1970年-2007年2月)进行了搜索。数据合成:蒽环类药物的泛滥可能具有毁灭性影响。这些药物渗入间质组织后,损害范围可能从轻度红斑和疼痛到严重的组织坏死。在处理这些伤害方面已经研究了许多因素。然而,几乎没有证据表明其疗效,治疗仍存在争议。已显示出可限制外渗损伤的非药物疗法包括局部组织冷却和患处升高。皮质类固醇,碳酸氢钠,透明质酸酶,高压氧,肝素级分,α-生育酚,N-乙酰半胱氨酸和粒细胞巨噬细胞集落刺激因子均显示无效或支持其使用的数据有限。在前瞻性研究中已显示局部二甲基亚砜(DMSO)可以限制外渗损伤的进程。在动物模型和病例报告中已经证明了右雷佐生在蒽环类药物外渗的治疗中有用。两项最近的前瞻性临床试验对在渗出后6小时内,渗出后24小时内1000 mg / m2和渗出后48小时后500 mg / m2静脉内右雷佐生进行了研究,这些数据支持在这种渗出中使用这种药物。在纳入的54例患者中,有98.2%避免了需要手术的坏死。结论:蒽环类药物外渗的最佳治疗方法包括局部组织冷却,患肢四肢抬高,右雷佐生给药和可能的局部DMSO。已经对许多其他药物进行了调查。然而,由于缺乏数据,因此不建议将其用于蒽环类药物外渗的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号